OncoMed (OMED) shareholders had a rough day, with potential issues with mild-to-moderate bone-related adverse events causing a halt in a phase 1 trial for two of the company's drugs. The big question, of course, is whether this makes for an attractive investment situation. Could this be an opportunity to get shares of a company paired with the likes of Celgene (CELG) and other big pharmas on several drug candidates for cheap?
In the video below, health care analysts Michael Douglass and David Williamson lay out OncoMed's strengths, but also the weaknesses that will keep them away from the stock for the time being.
